Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
Conditions
Interventions
Placebo
RSV preF Protein 50 mcg
+7 more
Locations
6
United States
Optimal Research
Huntsville, Alabama, United States
Optimal Research
San Diego, California, United States
Optimal Research
Melbourne, Florida, United States
Optimal Research
Peoria, Illinois, United States
Optimal Research
Rockville, Maryland, United States
Optimal Research
Austin, Texas, United States
Start Date
July 6, 2018
Primary Completion Date
May 16, 2022
Completion Date
May 16, 2022
Last Updated
May 25, 2025
NCT06716502
NCT06290258
NCT07310264
NCT00090662
NCT07483606
NCT06342713
Lead Sponsor
Janssen Vaccines & Prevention B.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions